Ashish K Khanna1,2, Leif Saager3, Sergio D Bergese4, Carla R Jungquist5, Hiroshi Morimatsu6, Shoichi Uezono7, Lian Kah Ti8, Roy Soto9, Wei Jiang10, Wolfgang Buhre11. 1. Wake Forest School of Medicine, Winston-Salem, NC, USA. ashish@or.org. 2. Outcomes Research Consortium, Cleveland, OH, USA. ashish@or.org. 3. Universitätsmedizin Göttingen, Göttingen, Germany. 4. Stony Brook Medicine, Stony Brook, NY, USA. 5. University at Buffalo School of Nursing, Buffalo, NY, USA. 6. Okayama University Hospital, Okayama, Japan. 7. Jikei University School of Medicine, Tokyo, Japan. 8. National University of Singapore, Singapore, Singapore. 9. Beaumont Hospital, Royal Oak, MI, USA. 10. Medtronic Inc., Mansfield, MA, USA. 11. University Medical Center, Utrecht, Netherlands.
Abstract
BACKGROUND: Opioid-induced respiratory depression is common on the general care floor. However, the clinical and economic burden of respiratory depression is not well-described. The PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial created a prediction tool to identify patients at risk of respiratory depression. The purpose of this retrospective sub-analysis was to examine healthcare utilization and hospital cost associated with respiratory depression. METHODS: One thousand three hundred thirty-five patients (N = 769 United States patients) enrolled in the PRODIGY trial received parenteral opioids and underwent continuous capnography and pulse oximetry monitoring. Cost data was retrospectively collected for 420 United States patients. Differences in healthcare utilization and costs between patients with and without ≥1 respiratory depression episode were determined. The impact of respiratory depression on hospital cost per patient was evaluated using a propensity weighted generalized linear model. RESULTS: Patients with ≥1 respiratory depression episode had a longer length of stay (6.4 ± 7.8 days vs 5.0 ± 4.3 days, p = 0.009) and higher hospital cost ($21,892 ± $11,540 vs $18,206 ± $10,864, p = 0.002) compared to patients without respiratory depression. Patients at high risk for respiratory depression, determined using the PRODIGY risk prediction tool, who had ≥1 respiratory depression episode had higher hospital costs compared to high risk patients without respiratory depression ($21,948 ± $9128 vs $18,474 ± $9767, p = 0.0495). Propensity weighted analysis identified 17% higher costs for patients with ≥1 respiratory depression episode (p = 0.007). Length of stay significantly increased total cost, with cost increasing exponentially for patients with ≥1 respiratory depression episode as length of stay increased. CONCLUSIONS: Respiratory depression on the general care floor is associated with a significantly longer length of stay and increased hospital costs. Early identification of patients at risk for respiratory depression, along with early proactive intervention, may reduce the incidence of respiratory depression and its associated clinical and economic burden. TRIAL REGISTRATION: ClinicalTrials.gov , NCT02811302 .
BACKGROUND: Opioid-induced respiratory depression is common on the general care floor. However, the clinical and economic burden of respiratory depression is not well-described. The PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial created a prediction tool to identify patients at risk of respiratory depression. The purpose of this retrospective sub-analysis was to examine healthcare utilization and hospital cost associated with respiratory depression. METHODS: One thousand three hundred thirty-five patients (N = 769 United States patients) enrolled in the PRODIGY trial received parenteral opioids and underwent continuous capnography and pulse oximetry monitoring. Cost data was retrospectively collected for 420 United States patients. Differences in healthcare utilization and costs between patients with and without ≥1 respiratory depression episode were determined. The impact of respiratory depression on hospital cost per patient was evaluated using a propensity weighted generalized linear model. RESULTS: Patients with ≥1 respiratory depression episode had a longer length of stay (6.4 ± 7.8 days vs 5.0 ± 4.3 days, p = 0.009) and higher hospital cost ($21,892 ± $11,540 vs $18,206 ± $10,864, p = 0.002) compared to patients without respiratory depression. Patients at high risk for respiratory depression, determined using the PRODIGY risk prediction tool, who had ≥1 respiratory depression episode had higher hospital costs compared to high risk patients without respiratory depression ($21,948 ± $9128 vs $18,474 ± $9767, p = 0.0495). Propensity weighted analysis identified 17% higher costs for patients with ≥1 respiratory depression episode (p = 0.007). Length of stay significantly increased total cost, with cost increasing exponentially for patients with ≥1 respiratory depression episode as length of stay increased. CONCLUSIONS: Respiratory depression on the general care floor is associated with a significantly longer length of stay and increased hospital costs. Early identification of patients at risk for respiratory depression, along with early proactive intervention, may reduce the incidence of respiratory depression and its associated clinical and economic burden. TRIAL REGISTRATION: ClinicalTrials.gov , NCT02811302 .
Authors: Lars W Andersen; Katherine M Berg; Maureen Chase; Michael N Cocchi; Joseph Massaro; Michael W Donnino Journal: Resuscitation Date: 2016-05-30 Impact factor: 5.262
Authors: Lorri A Lee; Robert A Caplan; Linda S Stephens; Karen L Posner; Gregory W Terman; Terri Voepel-Lewis; Karen B Domino Journal: Anesthesiology Date: 2015-03 Impact factor: 7.892
Authors: Gary M Oderda; R Scott Evans; James Lloyd; Arthur Lipman; Connie Chen; Michael Ashburn; John Burke; Matthew Samore Journal: J Pain Symptom Manage Date: 2003-03 Impact factor: 3.612
Authors: Ashish K Khanna; Frank J Overdyk; Christine Greening; Paola Di Stefano; Wolfgang F Buhre Journal: J Crit Care Date: 2018-06-18 Impact factor: 3.425
Authors: Zhuo Sun; Daniel I Sessler; Jarrod E Dalton; P J Devereaux; Aram Shahinyan; Amanda J Naylor; Matthew T Hutcherson; Patrick S Finnegan; Vikas Tandon; Saeed Darvish-Kazem; Shaan Chugh; Hussain Alzayer; Andrea Kurz Journal: Anesth Analg Date: 2015-09 Impact factor: 6.627